Correction of coagulopathy in warfarin associated cerebral hemorrhage

Current Opinion in Critical Care

Volumn 15, Issue 2, 2009, Pages 87-92

  Aiyagari, Venkatesh ^a   Testai, Fernando D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulation; Intracerebral hemorrhage; Therapy; Warfarin

Indexed keywords

FRESH FROZEN PLASMA; PHYTOMENADIONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEMOPHILIA B; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOELASTOGRAPHY; THROMBOPHILIA;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CEREBRAL HEMORRHAGE; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIIA; HUMANS; PLASMA; VITAMIN K; VITAMINS; WARFARIN;

EID: 67749106294     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3283269e4d     Document Type: Review

References (45)

1. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S-198S. Excellent review of pharmacodynamics and pharmacokinetics of warfarin. Includes recommendations for treatment of life-threatening bleeding in patients anticoagulated with warfarin.
2. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulantassociated intracerebral hemorrhage. Neurology 2007; 68:116-121.
3. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36:1588-1593.
4. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:257S-298S. Comprehensive review of incidence and risk factors for bleeding complications of warfarin and other anticoagulants.
5. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141:745-752.
6. Ueno H, Naka H, Ohshita T, et al. Association between cerebral microbleeds on T2*-weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. AJNR Am J Neuroradiol 2008; 29:1483-1486.
7. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471-1477.
8. Flaherty ML, Haverbusch M, Sekar P, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006; 5:197-201.
9. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71:1084-1089. Population based study of cerebral hemorrhage that concludes that warfarin use with INR>3.0 is associated with larger initial hemorrhage volumes.
10. Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39:2993-2996. An examination of patients with cerebral hemorrhage enrolled in the placebo arm of the CHANT study that shows that anticoagulant-associated cerebral hemorrhage has a higher expansion rate and mortality compared to patients with spontaneous cerebral hemorrhage.
11. Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63:1059-1064.
12. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89:278-283.
13. Zubkov AY, Mandrekar JN, Claassen DO, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol 2008; 65:1320-1325.
14. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006; 37:256-262.
15. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs. intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163:2469-2473.
16. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101:374-387.
17. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181:492-497.
18. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37:1465-1470.
19. Ozgonenel B, O'Malley B, Krishen P, et al. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 82:1091-1094.
20. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77:477-480.
21. Brody DL, Aiyagari V, Shackleford AM, et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2:263-267.
22. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37:151-155.
23. Lee SB, Manno EM, Layton KF, et al. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67:1272-1274.
24. Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008; 8:36-41.
25. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21:37-48.
26. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107 (Suppl 1):S53-S57.
27. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83:137-143. Review of published studies of prothrombin complex conjugates in the urgent reversal of warfarin associated coagulopathy.
28. Boulis NM, Bobek MP, Schmaier A, et al. Use of factor IX complex in warfarinrelated intracranial hemorrhage. Neurosurgery 1999; 45:1113-1118; discussion 1118-1119.
29. Cartmill M, Dolan G, Byrne JL, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14:458-461.
30. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23:972-977.
31. Sjoblom L, Hardemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32:2567-2574.
32. Yasaka M, Sakata T, Naritomi H, et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115:455-459.
33. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622-631. Results of a small prospective multicenter trial to investigate the safety and efficacy of Beriplex P/N, a prothrombin complex conjugate, in rapidly normalizing INR in patients with warfarin-associated coagulopathy and an indication for urgent reversal of coagulopathy.
34. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-2137. Landmark double-blind, placebo controlled, multicenter study of recombinant activated factor VII in patients with acute spontaneous cerebral hemorrhage. Patients treated with factor VII had significantly lower incidence of hematoma expansion but there was no significant difference in mortality or functional outcome.
35. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14:469-477.
36. Lin J, Hanigan WC, Tarantino M, et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98:737-740.
37. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79:1495-1500.
38. Ilyas C, Beyer GM, Dutton RP, et al. Recombinant factor VIIa for warfarinassociated intracranial bleeding. J Clin Anesth 2008; 20:276-279.
39. Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, et al. Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery 2005; 57:832-836; discussion 832-836.
40. Neal M, Crowther M, Douketis J, et al. Reversal of vitamin K antagonistassociated coagulopathy: a survey of current practice. Thromb Res 2008; 122:864-866.
41. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119:643-651.
42. Taketomi T, Szlam F, Levy JH, et al. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis 2008; 19:106-108.
43. Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48-53.
44. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004; 41:20-24.
45. Foerch C, Arai K, Jin G, et al. Experimental model of warfarin-associated intracerebral hemorrhage. Stroke 2008; 39:3397-3404. This study characterizes the first experimental model of warfarin-associated cerebral hemorrhage.